Detalhe da pesquisa
1.
Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial.
Adv Ther
; 39(8): 3789-3798, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35771353